Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study

International Journal of Radiation Oncology, Biology, Physics
Craig A SchulzTimothy J Kinsella

Abstract

To investigate the maximal tolerated dose of a continuous 28-day iododeoxyuridine (IUdr) infusion combined with hyperfractionated accelerated radiotherapy (HART); to analyze the percentage of IUdr-thymidine replacement in peripheral granulocytes as a surrogate marker for IUdr incorporation into tumor cells; to measure the steady-state serum IUdr levels; and to assess the feasibility of continuous IUdr infusion and HART in the management of malignant glioma. Patients were required to have biopsy-proven malignant glioma. Patients received 100 (n = 4), 200 (n = 3), 300 (n = 3), 400 (n = 6), 500 (n = 4), 625 (n = 5), or 781 (n = 6) mg/m(2)/d of IUdr by continuous infusion for 28 days. HART was started 7 days after IUdr initiation. The total dose was 70 Gy (1.2 Gy b.i.d. for 25 days with a 10-Gy boost [2.0 Gy for 5 Saturdays]). Weekly assays were performed to determine the percentage of IUdr-DNA replacement in granulocytes and serum IUdr levels using standard high performance liquid chromatography methods. Standard Phase I toxicity methods were used. Between June 1994 and August 1999, 31 patients were enrolled. No patient had Grade 3 or worse HART toxicity. Grade 3 or greater IUdr toxicity predominantly included neutropenia (n = 3),...Continue Reading

References

Jun 1, 1991·International Journal of Radiation Oncology, Biology, Physics·R RodriguezT J Kinsella
Apr 1, 1990·International Journal of Radiation Oncology, Biology, Physics·A J FornaceT J Kinsella
Sep 4, 1996·Journal of the National Cancer Institute·C J McGinnT S Lawrence
May 15, 2003·Journal of Physiology and Biochemistry·F J CasadoM Pastor-Anglada

❮ Previous
Next ❯

Citations

Oct 12, 2010·International Journal of Radiation Oncology, Biology, Physics·Joseph P DugasKenneth R Hogstrom
Sep 14, 2010·Seminars in Radiation Oncology·Conchita Vens, Adrian C Begg
Oct 31, 2007·International Journal of Radiation Oncology, Biology, Physics·Timothy J KinsellaGregory Berk
Mar 6, 2012·The FEBS Journal·Tine SkovgaardBirgitte Munch-Petersen
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna S Shewach, Theodore S Lawrence
May 31, 2017·Radiation Research·Mohammad RezaeeDavid A Jaffray
May 9, 2016·Chemphyschem : a European Journal of Chemical Physics and Physical Chemistry·Samanta MakuratJanusz Rak
Jan 10, 2016·Experimental Biology and Medicine·Samideh KhoeiFariborz Faeghi
Feb 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Timothy J Kinsella
Jul 25, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Timothy KinsellaJerry M Collins
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuji SeoTimothy J Kinsella

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.